Transcarent completed its acquisition of Accolade on April 8, 2025, following a definitive agreement announced on January 8, 2025. The transaction is structured as a full‑takeover, with Accolade ceasing to be a Nasdaq‑listed company and becoming a privately held subsidiary within the combined group. The strategic rationale is centered on the creation of a unified, AI‑driven “One Place for Health and Care” platform. Transcarent’s WayFinding experience, generative AI‑powered navigation, and complex‑care pathways in Cancer Care, Surgery Care, and Weight Health are combined with Accolade’s strengths in health advocacy, expert medical opinions (EMO), and virtual primary care. This integration allows members to access benefits navigation, clinical guidance, and end‑to‑end care delivery through a single interface, with the explicit goal of improving utilization patterns, lowering total care costs, and enhancing member experience for employers and payers. The combined organization now serves over 20 million members and more than 1,700 employer and health‑plan clients, creating a large‑scale, digitally‑native health services platform with significant optionality for cross‑selling, technology integration, and further ecosystem expansion.

ACCOLADE, which reported an EBITDA margin of LOGIN in 2025, is valued in this transaction at an EV/EBITDA multiple of LOGIN, representing a LOGIN premium to the average currently observed in the Healthcare & Pharma sector (13.4x).

Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.